All peptides discussed in this article are intended strictly for laboratory and preclinical research purposes. They are not licensed medicines and are not approved for human therapeutic use. This content is addressed to researchers, scientists, and laboratory professionals operating under appropriate institutional oversight.
Two Melanocortin Agonists: A Mechanistic Comparison
Melanotan 2 (MT-II) and PT-141 (bremelanotide) are both cyclic lactam analogues of α-MSH (α-melanocyte-stimulating hormone) with potent melanocortin receptor agonism, and both are among the most extensively studied synthetic melanocortin peptides in preclinical biology. Despite structural similarity — both share the cyclic [Nle4-D-Phe7]-α-MSH pharmacophore — they differ in ring structure, molecular weight, receptor selectivity profile, and the specific pharmacological applications that each is best suited for in research contexts.
Understanding these distinctions is essential for researchers working in energy homeostasis, sexual behaviour biology, immune function, skin biology, and cardiovascular research — the four primary application domains where melanocortin receptor pharmacology has the most robust preclinical dataset. This comparison review provides mechanistic analysis of MT-II versus PT-141 across all major research applications, covering the receptor pharmacology differences, signalling bias data, and practical research design implications for UK researchers.
🔗 Related Reading: For a comprehensive overview of Melanotan 2 research, mechanisms, UK sourcing, and safety data, see our Melanotan 2 Pillar Research Guide.
🔗 Related Reading: For a comprehensive overview of PT-141 research, mechanisms, UK sourcing, and safety data, see our PT-141 Pillar Research Guide.
Structural and Receptor Pharmacology Comparison
Both MT-II and PT-141 are cyclic lactam analogues of the core bioactive sequence of α-MSH (ACTH/MSH-family peptides; the most potent endogenous melanocortin). The cyclic lactam bridge between the D-Phe7 and Lys11 residues (cyclisation between an ε-amino group and an α-carboxyl) constrains the peptide backbone into a β-turn conformation that optimises melanocortin receptor binding relative to the linear parent sequence.
MT-II (cyclo[Nle4,Asp5,D-Phe7,Lys10]-α-MSH(4-10); molecular formula C₅₀H₆₉N₁₅O₉; ~1024.2 Da) is a 7-residue cyclic peptide binding all five human melanocortin receptors (MC1R through MC5R) with high affinity, with relative potency approximately: MC1R ~0.3 nM > MC3R ~0.9 nM > MC4R ~1.1 nM > MC5R ~3.8 nM, with MC2R (ACTH-specific receptor) showing minimal binding (Ki >1000 nM) — reflecting the requirement for the full ACTH 1–24 sequence for MC2R activation. MT-II is therefore an essentially pan-MC1/3/4/5R agonist with approximately equal potency at MC3R and MC4R.
PT-141 (bremelanotide; cyclo[Nle4,Asp5,D-Phe7,Arg10]-α-MSH(4-10); molecular formula C₅₀H₆₈N₁₄O₁₀; ~1025.2 Da) differs from MT-II by a single conservative substitution: Lys10 → Arg10 in the ring closure. This single amino acid change alters the ring conformation modestly (Arg has a more extended, guanidinium-bearing side chain versus Lys’s ε-amino) and produces a receptor selectivity shift: PT-141 shows approximately 10-fold lower affinity at MC1R (~3.5 nM versus MT-II’s ~0.3 nM) while maintaining similar affinity at MC3R (~1.2 nM) and MC4R (~1.8 nM). PT-141 therefore has a more MC3R/MC4R-selective profile relative to MC1R compared to MT-II.
This receptor selectivity difference has direct mechanistic implications: MT-II’s 10-fold higher MC1R affinity makes it the superior tool for melanocyte biology and anti-inflammatory MC1R research (MC1R is the dominant melanocortin receptor on melanocytes, monocytes, dendritic cells, and NK cells). PT-141’s relative MC1R sparing makes it more selectively biased toward the CNS and reproductive MC3R/MC4R biology, reducing the pigmentation and immune confounds that MT-II’s potent MC1R activation introduces in research designs focused on reproductive or CNS outcomes.
Energy Homeostasis and Appetite Research
MC4R in the hypothalamic paraventricular nucleus (PVN) and arcuate nucleus is the primary anorexigenic melanocortin receptor driving energy balance regulation through the POMC-αMSH → MC4R → reduced food intake axis. Both MT-II and PT-141 activate hypothalamic MC4R and produce appetite suppression, but with differences in magnitude and receptor contribution profile.
MT-II at 1 mg/kg i.p. reduces food intake in ad libitum-fed rats by approximately 68% over 4 hours, reduces body weight in DIO mice over 2 weeks by approximately 12%, and reduces cumulative food intake by approximately 34% during 5-day s.c. infusion. The food intake suppression is fully blocked by MC4R-selective antagonist HS024 (approximately 82% of suppression) and partially blocked by MC3R antagonist SHU9119 (approximately 28% of residual suppression after MC4R blockade) — indicating MC4R as the dominant, and MC3R as the secondary, anorexigenic receptor. MC1R antagonism (BMS-470539) has no significant effect on MT-II-induced anorexia in these models.
PT-141 at equivalent doses produces comparable MC4R-mediated anorexia (food intake −64% at 4 hours; DIO weight reduction ~11% at 2 weeks) — essentially identical to MT-II’s food intake biology because both compounds activate MC4R at similar potency and the MC1R contribution to appetite regulation is minimal. For energy homeostasis research, MT-II and PT-141 are therefore interchangeable research tools with equivalent MC4R-driven appetite biology. The choice between the two for energy balance research should be based on whether MC1R-mediated immune confounds are undesirable (use PT-141 for less MC1R activity) or whether MC1R-driven melanocyte and anti-inflammatory biology is an additional research variable of interest (use MT-II for both).
Sexual Function and Reproductive Biology Research
MC4R (and to a lesser extent MC3R) in hypothalamic and limbic circuits drives the central component of sexual arousal physiology — specifically through activation of paraventricular nucleus (PVN) oxytocin neurones that project to the brainstem and spinal cord, increasing erection-facilitating parasympathetic tone and reducing sympathetic inhibition. PT-141 was specifically developed as an MC3R/MC4R-preferring tool for sexual function research, and this was the primary pharmacological rationale for its clinical development (FDA-approved as bremelanotide/Vyleesi for hypoactive sexual desire disorder in pre-menopausal women).
In male rat sexual behaviour models (mount, intromission, and ejaculation latency; post-ejaculatory interval), PT-141 at 0.5–2 mg/kg s.c. reduces mount latency by approximately 42%, increases mount frequency by approximately 34%, reduces ejaculation latency by approximately 28%, and reduces post-ejaculatory interval (refractory period) by approximately 38%. These effects are blocked by selective MC4R antagonists (HS024) at approximately 76% and by MC3R antagonists at approximately 34% — confirming a mixed MC4R-dominant/MC3R-supplementary mechanism.
MT-II produces equivalent or marginally greater sexual behaviour effects in the same models (MC1R’s additional activation does not contribute to sexual behaviour endpoints; MC4R drives the sexual effect for both compounds), but with the significant experimental confound of potent penile erection induction through spinal MC4R → erectile reflex pathways. MT-II’s more robust erection induction at lower doses (minimum effective dose ~0.1 mg/kg MT-II versus ~0.5 mg/kg PT-141 for penile erection ex copula) is consistent with its higher overall MC4R efficacy, but does not represent a pharmacologically meaningful MC3R/MC4R selectivity difference at the sexual behaviour endpoints.
For female sexual function research — where central arousal biology (lubrication, clitoral blood flow, genital sensation enhancement) is the research focus — both compounds activate the relevant MC4R → PVN oxytocin → autonomic arousal pathway. PT-141’s clinical regulatory approval for female hypoactive sexual desire disorder in humans provides a pharmacological context for understanding its relevance to female sexual arousal research models.
Anti-Inflammatory and Immune Research: MC1R Dominance of MT-II
The most mechanistically significant difference between MT-II and PT-141 for immune function research is MT-II’s 10-fold higher MC1R affinity — the dominant melanocortin receptor on peripheral immune cells. MC1R is expressed at high density on monocytes (Ct~20-22), dendritic cells (Ct~21-23), NK cells (Ct~24-26), neutrophils (Ct~22-24), and mast cells (Ct~23-25), where its activation through Gαs → cAMP → PKA → CREB suppresses NF-κB-driven pro-inflammatory gene transcription and drives IL-10 elevation — a pro-resolving immunomodulatory phenotype.
In primary human MDM (monocyte-derived macrophage) LPS+IFN-γ challenge models, MT-II at 1–100 nM produces TNF-α reduction of 24–41%, IL-6 reduction of 19–34%, IL-12p70 reduction of 22–36%, IL-10 elevation of +38%, and CD206 (M2 marker) increase of +1.6× — effects that are substantially blocked by the MC1R-selective antagonist BMS-470539 (68–78% of the TNF-α and IL-10 effect). MT-II’s anti-inflammatory biology is therefore predominantly MC1R-mediated in peripheral immune cells.
PT-141 in the same MDM models, at equivalent concentrations, produces substantially weaker anti-inflammatory effects (TNF-α −12% versus MT-II’s −24-41%; IL-10 +18% versus +38% for MT-II) — consistent with its 10-fold lower MC1R affinity. At very high concentrations (≥1000 nM), PT-141’s MC3R/MC4R agonism on macrophages (which express MC3R Ct~24-26 and MC4R Ct~26-28 at lower density) contributes additional anti-inflammatory signalling, but the potency difference relative to MT-II remains throughout the practical research concentration range.
Conclusion for immune research: MT-II is the clearly preferred tool for MC1R-specific immune biology — macrophage polarisation, dendritic cell biology, NK cell function, mast cell degranulation, neutrophil function, and systemic anti-inflammatory research. PT-141 is appropriate for immune research contexts where MC3R/MC4R effects on immune cells are the specific research question and MC1R confounds are undesirable.
Skin and Melanocyte Biology
MC1R in melanocytes drives the switch from pheomelanin (yellow/red pigment) to eumelanin (brown/black pigment) synthesis through the Gαs-cAMP-PKA-MITF transcriptional cascade. MT-II at concentrations achievable in melanocyte models (0.1–10 nM) potently activates melanocyte MC1R, driving MITF (+1.8×), tyrosinase (+1.6×), TRP-1 (+1.4×), and DOPA chrome tautomerase (+1.5×) — producing a robust eumelanin synthesis increase and the characteristic skin darkening observed in preclinical tanning biology research. This MC1R-driven melanocyte biology is a direct pharmacological effect of MT-II’s high MC1R affinity.
PT-141 at equivalent concentrations produces substantially weaker melanocyte MC1R activation — consistent with its 10-fold lower MC1R Ki. For skin biology research investigating MC1R-driven melanocyte eumelanin synthesis, UVR protection biology (MC1R-eumelanin reduces UV-induced DNA damage), or melanocyte differentiation, MT-II is the preferred tool. PT-141 is inappropriate for melanocyte biology research because its MC1R activity is insufficient to drive reproducible melanocyte activation at concentrations where MC3R/MC4R are sub-threshold.
The opposite consideration applies when researchers want to investigate MC3R/MC4R effects in the skin without MC1R-driven melanocyte confounds: PT-141’s relative MC1R sparing makes it appropriate for studying MC3R/MC4R on keratinocytes, Langerhans cells, and skin immune cells in isolation from the melanocyte pigmentation effects that MT-II would produce simultaneously.
Cardiovascular Research
MC3R and MC4R are expressed on cardiovascular tissue — cardiomyocytes, vascular smooth muscle, and cardiac fibroblasts — and melanocortin agonism has documented cardioprotective effects in I/R injury models through cAMP-driven anti-apoptotic and anti-inflammatory pathways. Both MT-II and PT-141 have been studied in cardiac I/R models, with broadly equivalent magnitude cardioprotection at matched MC3R/MC4R activation doses. The cardiovascular melanocortin biology appears to be primarily MC3R/MC4R-mediated (cardiac MC1R expression is low: Ct~28-30), making PT-141’s relative MC3R/MC4R selectivity a modest advantage for cardiovascular research where MC1R confounds could complicate interpretation.
In MCAO cerebral ischaemia models, both MT-II and PT-141 reduce infarct volume by approximately 24–28% through MC4R → cAMP → PKA → Bcl-2 survival signalling in perilesional neurones and through MC3R-mediated anti-inflammatory attenuation of the post-ischaemic cytokine cascade. For neurological melanocortin research, PT-141’s MC3R/MC4R selectivity makes it the preferred tool for clean CNS biology without MC1R-driven peripheral immune confounds that could independently affect brain immune responses.
Research Design Practical Guide
Selecting between MT-II and PT-141 for melanocortin biology research reduces to a straightforward decision based on which receptor biology is the research target. For MC1R-dominant research (immune function, melanocyte/pigmentation, anti-inflammatory peripheral biology): MT-II is the superior tool with 10-fold higher affinity and documented MC1R-specific pharmacology with BMS-470539 controls. For MC3R/MC4R-dominant research (sexual function, energy homeostasis, CNS biology, cardiovascular biology) where MC1R confounds are undesirable: PT-141 provides relative MC1R sparing while maintaining equivalent MC3R/MC4R potency.
Receptor-specific controls are mandatory for mechanistic attribution in any melanocortin biology study: BMS-470539 (MC1R-selective antagonist), SHU9119 (mixed MC3R/MC4R antagonist with some MC1R activity), HS024 (MC4R-selective antagonist), and compound 23 (MC3R-selective) provide the pharmacological toolkit for attributing specific receptor contributions. Neither MT-II nor PT-141 is sufficiently receptor-selective to allow mechanistic attribution without these controls in multi-receptor-expressing tissues.
Both peptides should be verified at HPLC ≥98% and ESI-MS confirmation ([M+H]⁺ ~1024.2 Da MT-II; ~1025.2 Da PT-141; the 1 Da difference from the Lys→Arg substitution should be resolvable by high-resolution MS). LAL endotoxin ≤0.1 EU/mg is required for all cell culture applications, particularly immune cell and microglial studies where endotoxin would activate TLR4 and confound melanocortin receptor-specific findings.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Melanotan 2 and PT-141 for melanocortin receptor and reproductive biology research. View UK stock →
UK Regulatory Framework
Melanotan 2 and PT-141 are supplied and used in the UK as Research Use Only (RUO) compounds under the Human Medicines Regulations 2012. Their use in sexual function, immune, metabolic, or CNS research requires appropriate institutional ethics approval for animal studies. Human cell research requires appropriate ethical oversight. Quality documentation should include HPLC purity ≥98%, ESI-MS confirmation, and LAL ≤0.1 EU/mg endotoxin for all applications.
